Form D · Biotechnology
Evozyne, Inc.
Chicago, IL · CIK 0001811288
Offering snapshot reported Sep 29, 2023 · SEC filing
- Reported sold
- $81M Offering amount: $100M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 14, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 29, 2023 | Initial | $81,000,122 | No comparison | 29 | SEC filing |
| Apr 22, 2021 | Initial | $54,183,709 | No comparison | Not reported | SEC filing |
| May 7, 2020 | Initial | $9,183,673 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.05M
- Finders' fees
- $0
- Form D file number
- 021-493466
Total sold includes sale of secured conv promissory notes amounting to $40500061 in aggregate. Total Remaining includes approx $9,499,940 of remaining equity to be sold & approx $9499940 of remaining secured convertible promissory notes to be sold.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Paragon Health Capital, LLC | 300729 |
Source: Form D, filed Sep 29, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey S. Aronin | Director, Executive |
| Mike Gamson | Director, Executive |
| Antonio Gracias | Director |
| Aleina Lee | Executive |
| Patrick J. Morris | Director, Executive |
| Darien Parhad | Executive |
| Arjun Rallapalli | Executive |
| Rama Ranganathan | Director, Executive |
| Matthew Rizzo | Director |
| Jude M. Sullivan | Executive |
| Aris Theologis | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
330 N. Wabash Avenue Suite 3500
Chicago, IL, 60611
Chicago, IL, 60611